Product Description
Imipenem is in a class of medications called carbapenem antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a686013.html)
Mechanisms of Action: PBP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Urinary Tract Infections | Nephritis | Pyelonephritis | Endocarditis | Seizures | Endocarditis, Bacterial | Respiratory Tract Infections | Urinary Tract Infections
Known Adverse Events: Hypertension | Phlebitis | Headache | Diarrhea | Tachycardia | Hypotension | Seizures | Dizziness | Pain Unspecified | Erythema | Urticaria | Enteritis | Gastroenteritis | Pruritus | Candidiasis | Candidiasis, Oral | Anuria | Oliguria
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, France, Israel, Spain, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Communicable Diseases|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Pyelonephritis|Urinary Tract Infections
Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia
Phase 1: Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HRS-8427-302 | P3 |
Recruiting |
Urinary Tract Infections|Pyelonephritis|Communicable Diseases |
2025-11-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis |
2025-06-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis |
2025-06-01 |
|
| EudraCT no. 2022-000061-40 | P3 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis |
2025-06-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2025-04-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2025-04-01 |
|
| REITAB-2 | P3 |
Recruiting |
Pneumonia, Bacterial|Pneumonia, Ventilator-Associated |
2025-04-01 |
|
| HRS-8427-202 | P2 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis|Communicable Diseases |
2024-06-01 |
24% |
| HRS-8427-202 | P2 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis|Communicable Diseases |
2024-06-01 |
24% |
| HRS-8427-202 | P2 |
Not yet recruiting |
Urinary Tract Infections|Pyelonephritis|Communicable Diseases |
2024-06-01 |
24% |